Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 265 articles: HTML format

Single Articles

June 2021
1. TARPGAARD LS, Andersen PV, Ogaard N, Demuth C, et al
   Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer.
   Ann Oncol. 2021;32:805-806.
   PubMed    
   
   
   April 2021
2. GROTHEY A, Fakih M, Tabernero J
   Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
   Ann Oncol. 2021 Apr 6. pii: S0923-7534(21)01112.
   PubMed     Abstract available
   
   
   March 2021
3. YUE Y, Hur J, Cao Y, Tabung FK, et al
   Prospective Evaluation of Dietary and Lifestyle Pattern Indices with Risk of Colorectal Cancer in a Cohort of Younger Women.
   Ann Oncol. 2021 Mar 31. pii: S0923-7534(21)01097.
   PubMed     Abstract available
   
   
   
4. CARMONA-BAYONAS A, Jimenez-Fonseca P, Valenti V, Salazar R, et al
   Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA.
   Ann Oncol. 2021 Mar 16. pii: S0923-7534(21)00878.
   PubMed    
   
   
   November 2020
5. GLYNNE-JONES R, Meadows HM, Lopes A, Muirhead R, et al
   Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs.
   Ann Oncol. 2020;31:1587-1588.
   PubMed    
   
   
   
6. JONES H, Gilbert D, Gilbert A, Jacobs C, et al
   DPD testing in radical chemoradiation for anal squamous cell carcinoma.
   Ann Oncol. 2020;31:1580.
   PubMed    
   
   
   October 2020
7. YAMAZAKI K, Yamanaka T, Shiozawa M, Manaka D, et al
   Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial.
   Ann Oncol. 2020 Oct 26. pii: S0923-7534(20)42983.
   PubMed     Abstract available
   
   
   
8. PRETTA A, Trevisi E, Bregni G, Deleporte A, et al
   Treatment compliance in early-stage anal cancer.
   Ann Oncol. 2020;31:1282-1284.
   PubMed    
   
   
   
9. MANN EH, Maughan TS
   Fusobacterium nucleatum, rectal cancer and radiotherapy.
   Ann Oncol. 2020;31:1277-1278.
   PubMed    
   
   
   
10. SERNA G, Ruiz-Pace F, Hernando J, Alonso L, et al
    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
    Ann Oncol. 2020;31:1366-1375.
    PubMed     Abstract available
    
    
    September 2020
11. JAIN A, Sjoquist K, Yip D
    ESMO Localized colon cancer guidelines: "Can we improve on our surveillance protocols?"
    Ann Oncol. 2020 Sep 22. pii: S0923-7534(20)42463.
    PubMed    
    
    
    
12. BOSETTI C, Santucci C, Gallus S, La Vecchia C, et al
    Reply to the Letter to the Editor 'Aspirin to prevent gastrointestinal cancer - but recent trial data don't fit' by Jacobsen and colleagues.
    Ann Oncol. 2020;31:1263.
    PubMed    
    
    
    
13. HOLCH JW, Heinemann V
    Reply to 'Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?' by Evesque et al.
    Ann Oncol. 2020;31:1261-1262.
    PubMed    
    
    
    
14. JACOBSEN AP, Khiew YC, Blumenthal RS, Martin SS, et al
    Aspirin to prevent gastrointestinal cancer - but recent trial data do not fit.
    Ann Oncol. 2020;31:1262-1263.
    PubMed    
    
    
    August 2020
15. SELIGMANN JF, Elliott F, Richman S, Hemmings G, et al
    Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.
    Ann Oncol. 2020;31:1021-1029.
    PubMed     Abstract available
    
    
    July 2020
16. TARAZONA N, Roda D, Rosello S, Huerta M, et al
    New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing.
    Ann Oncol. 2020 Jul 22. pii: S0923-7534(20)39950.
    PubMed    
    
    
    
17. ARGILES G, Tabernero J, Labianca R, Hochhauser D, et al
    Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
    Ann Oncol. 2020 Jul 10. pii: S0923-7534(20)39932.
    PubMed    
    
    
    
18. PAGES F, Andre T, Taieb J, Vernerey D, et al
    Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39900.
    PubMed    
    
    
    
19. EVESQUE L, Francois E, Milano G
    Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?
    Ann Oncol. 2020;31:964-965.
    PubMed    
    
    
    June 2020
20. RODA D, Rosello S, Huerta M, Cervantes A, et al
    Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.
    Ann Oncol. 2020 Jun 13. pii: S0923-7534(20)39872.
    PubMed    
    
    
    
21. MAURI G, Arena S, Siena S, Bardelli A, et al
    The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer.
    Ann Oncol. 2020 Jun 5. pii: S0923-7534(20)39869.
    PubMed     Abstract available
    
    
    
22. VAN CUTSEM E, Danielewicz I, Saunders MP, Pfeiffer P, et al
    Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.
    Ann Oncol. 2020 Jun 1. pii: S0923-7534(20)39866.
    PubMed     Abstract available
    
    
    May 2020
23. BOSETTI C, Santucci C, Gallus S, Martinetti M, et al
    Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019.
    Ann Oncol. 2020;31:558-568.
    PubMed     Abstract available
    
    
    April 2020
24. YOSHINO T, Lenz HJ
    Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Giuseppe et al.
    Ann Oncol. 2020 Apr 30. pii: S0923-7534(20)39311.
    PubMed    
    
    
    
25. PAGES F, Andre T, Taieb J, Vernerey D, et al
    Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Ann Oncol. 2020 Apr 12. pii: S0923-7534(20)36415.
    PubMed     Abstract available
    
    
    
26. COLLOCA G, Venturino A, Guarneri D
    Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil.
    Ann Oncol. 2020 Apr 9. pii: S0923-7534(20)36409.
    PubMed    
    
    
    February 2020
27. BRIDGEWATER J
    Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)35948.
    PubMed    
    
    
    
28. ANDRE T, Vernerey D, Im SA, Bodoky G, et al
    Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
    Ann Oncol. 2020;31:246-256.
    PubMed     Abstract available
    
    
    January 2020
29. LEE H, Sha D, Foster NR, Shi Q, et al
    Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
    Ann Oncol. 2020 Jan 25. pii: S0923-7534(20)35944.
    PubMed     Abstract available
    
    
    
30. SALEM ME, Yin J, Goldberg RM, Pederson LD, et al
    Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35924.
    PubMed     Abstract available
    
    
    
31. YOSHINO T, Cleary JM, Van Cutsem E, Mayer RJ, et al
    Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    Ann Oncol. 2020;31:88-95.
    PubMed     Abstract available
    
    
    
32. HOLCH JW, Held S, Stintzing S, Fischer von Weikersthal L, et al
    Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
    Ann Oncol. 2020;31:72-78.
    PubMed     Abstract available
    
    
    
33. MARTINELLI E, Ciardiello D, Martini G, Troiani T, et al
    Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
    Ann Oncol. 2020;31:30-40.
    PubMed     Abstract available
    
    
    
34. KASI PM, Grothey A
    Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
    Ann Oncol. 2020;31:15-16.
    PubMed    
    
    
    December 2019
35. MARMORINO F, Rossini D, Lonardi S, Moretto R, et al
    Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019;30:1969-1977.
    PubMed     Abstract available
    
    
    November 2019
36. STINTZING S, Wirapati P, Lenz HJ, Neureiter D, et al
    Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Ann Oncol. 2019;30:1796-1803.
    PubMed     Abstract available
    
    
    
37. SVEEN A, Cremolini C, Dienstmann R
    Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
    Ann Oncol. 2019;30:1682-1685.
    PubMed    
    
    
    
38. TARAZONA N, Gimeno-Valiente F, Gambardella V, Zuniga S, et al
    Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Ann Oncol. 2019;30:1804-1812.
    PubMed     Abstract available
    
    
    
39. STINTZING S, Wirapati P, Lenz HJ, Neureiter D, et al
    Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Ann Oncol. 2019;30:1796-1803.
    PubMed     Abstract available
    
    
    
40. SVEEN A, Cremolini C, Dienstmann R
    Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
    Ann Oncol. 2019;30:1682-1685.
    PubMed    
    
    
    October 2019
41. MARMORINO F, Rossini D, Lonardi S, Moretto R, et al
    Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019 Oct 1. pii: 5579862. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. DIENSTMANN R, Villacampa G, Sveen A, Mason MJ, et al
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Ann Oncol. 2019;30:1622-1629.
    PubMed     Abstract available
    
    
    
43. NYAMUNDANDA G, Fontana E, Sadanandam A
    Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
    Ann Oncol. 2019;30:1538-1540.
    PubMed    
    
    
    September 2019
44. TARAZONA N, Gimeno-Valiente F, Gambardella V, Zuniga S, et al
    Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Ann Oncol. 2019 Sep 28. pii: 5574388. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. RODA D, Rosello S, Cervantes A
    Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.
    Ann Oncol. 2019;30:1409-1410.
    PubMed    
    
    
    
46. TAIEB J, Shi Q, Pederson L, Alberts S, et al
    Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Ann Oncol. 2019;30:1466-1471.
    PubMed     Abstract available
    
    
    August 2019
47. NYAMUNDANDA G, Fontana E, Sadanandam A
    Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
    Ann Oncol. 2019 Aug 29. pii: 5556307. doi: 10.1093.
    PubMed    
    
    
    
48. DIENSTMANN R, Villacampa G, Sveen A, Mason MJ, et al
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Ann Oncol. 2019 Aug 27. pii: 5555302. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548994. doi: 10.1093.
    PubMed    
    
    
    
50. GLYNNE-JONES R
    Extending the interval to surgery in rectal cancer and filling the time with chemotherapy-how much is enough?
    Ann Oncol. 2019;30:1188-1190.
    PubMed    
    
    
    July 2019
51. TAIEB J, Shi Q, Pederson L, Alberts S, et al
    Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies.
    Ann Oncol. 2019 Jul 3. pii: 5527754. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. SCHROCK AB, Ouyang C, Sandhu J, Sokol E, et al
    Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Ann Oncol. 2019;30:1096-1103.
    PubMed     Abstract available
    
    
    
53. HAMFJORD J, Guren TK, Dajani O, Johansen JS, et al
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Ann Oncol. 2019;30:1088-1095.
    PubMed     Abstract available
    
    
    
54. KOLESNIK O, Lukashenko A, Ostapenko Y, Chorna N, et al
    Laparoscopic liver resection in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv99.
    PubMed    
    
    
    
55. GUETTITI TOUNSI H, Wider D, Ben Ayed I, Habbachi A, et al
    Colorectal cancer in young Tunisian patients: clinical, histopathological and RAS testing data.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    
    
    
    
56. DASH P, Topi G, Sjolander A
    To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    
    
    
    
57. ALIANE H, Ghomari-Bezzar S
    The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    
    
    
    
58. LUKASHENKO A, Kolesnik O, Chorna N, Ostapenko Y, et al
    Simultaneous lungs and liver resections in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv98-iv99.
    PubMed    
    
    
    
59. ALIANE H, Ghomari-Bezzar S
    Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed    
    
    
    
60. AYARI J, Karrit S, Guesmi R, Zribi A, et al
    Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A prospective study in 60 patients in Tunisia.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed    
    
    
    
61. DIAZ C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, et al
    Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed    
    
    
    
62. ROSSAT S, Lefevre M, Le Berre N, Dorel M, et al
    Turnaround time < 7 days with a fully automated assay for RAS mutations in metastatic colorectal cancer: a pilot project in real-life conditions.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed    
    
    
    
63. JAVED H, Faisal M, Khan J, Anwar H, et al
    Higher expression of ERBB2, KRAS and down-regulation of APC, NF1 genes in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv94.
    PubMed    
    
    
    
64. HISAMATSU A, Ikusue T, Toshima H, Kobayashi K, et al
    Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy.
    Ann Oncol. 2019;30 Suppl 4:iv93.
    PubMed    
    
    
    
65. BELAID I, Khechine W, Saad A, Fki A, et al
    Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia.
    Ann Oncol. 2019;30 Suppl 4:iv93-iv94.
    PubMed    
    
    
    
66. VITALE P, Zanaletti N, Vitiello P, Martinelli E, et al
    Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data.
    Ann Oncol. 2019;30 Suppl 4:iv91.
    PubMed    
    
    
    
67. DE FALCO V, Vitiello P, Giunta E, Ciardiello D, et al
    Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience.
    Ann Oncol. 2019;30 Suppl 4:iv90.
    PubMed    
    
    
    
68. MARAVIC Z, Benedict A, Komlos K, Lemmens L, et al
    Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey.
    Ann Oncol. 2019;30 Suppl 4:iv90-iv91.
    PubMed    
    
    
    
69. TOMAS T, Nogueira-Costa G, Eiriz I, Vitorino M, et al
    Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal.
    Ann Oncol. 2019;30 Suppl 4:iv88.
    PubMed    
    
    
    
70. D'ARCANGELO M, Buonerba C, Avallone A, Dazzi C, et al
    The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study.
    Ann Oncol. 2019;30 Suppl 4:iv87-iv88.
    PubMed    
    
    
    
71. BENSI M, Calegari M, Basso M, Orlandi A, et al
    Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study).
    Ann Oncol. 2019;30 Suppl 4:iv87.
    PubMed    
    
    
    
72. RODRIGUEZ-COBOS J, Vinal D, Poves C, Fernandez-Acenero M, et al
    DeltaNp73 and Delta133p53 in liquid biopsy as early diagnostic markers for colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv86-iv87.
    PubMed    
    
    
    
73. BEN NASR S, Alibi S, Msekni I, Zribi A, et al
    Role of TILS in predicting evolution of metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv85.
    PubMed    
    
    
    
74. MIHAYLOVA Z, Ivanova D, Mihaylova G, Tasinov O, et al
    Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease.
    Ann Oncol. 2019;30 Suppl 4:iv81-iv82.
    PubMed    
    
    
    
75. PRETTA A, Lai E, Liscia N, Impera V, et al
    Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience.
    Ann Oncol. 2019;30 Suppl 4:iv81.
    PubMed    
    
    
    
76. ZHENG Q, Peng P
    Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv8.
    PubMed    
    
    
    
77. BASILE D, Pelizzari G, Di Nardo P, Corvaja C, et al
    The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA).
    Ann Oncol. 2019;30 Suppl 4:iv79.
    PubMed    
    
    
    
78. VAN CUTSEM E, Shitara K, Deng W, Vaury A, et al
    Gevokizumab, an interleukin-1beta (IL-1beta) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): "first-in-cancer" phase Ib study.
    Ann Oncol. 2019;30 Suppl 4:iv77-iv78.
    PubMed    
    
    
    
79. RUIZ-VOZMEDIANO J, Gutierrez-Martinez A, Postigo-Martin P, Cruz-Fernandez M, et al
    Efficacy of a therapeutic exercise program on autonomic nervous system function, cardiac function and functional capacity in colorectal cancer survivors: a randomized controlled pilot study.
    Ann Oncol. 2019;30 Suppl 4:iv77.
    PubMed    
    
    
    
80. ODENY T, Farha N, Hildebrand H, Allen J, et al
    Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv73.
    PubMed    
    
    
    
81. CALDERILLO-RUIZ G, Heredia D, Lopez H, Carbajal B, et al
    Retroperitoneal lymph node metastases as a prognosis factor in overall survival in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv72.
    PubMed    
    
    
    
82. NAGASAKA T, Tanioka H, Nyuya A, Katata Y, et al
    Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 4:iv71.
    PubMed    
    
    
    
83. MARINHO J, Neto E, Leao I, Silva J, et al
    Liquid biopsy for RAS mutational status analysis in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv69-iv70.
    PubMed    
    
    
    
84. BEN KRIDIS W, Mnif A, Khmiri S, Feki J, et al
    Right-sided versus left-sided metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv68.
    PubMed    
    
    
    
85. CIPRIANO A, Tavares A, Soares A, Mesquita A, et al
    The importance of laterality in colorectal cancer predicting response to therapeutics - retrospective study evaluating differences between right and left colon in stage IV colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv67-iv68.
    PubMed    
    
    
    
86. OMRCEN T, Katic A, Tomic S, Eterovic D, et al
    Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
    Ann Oncol. 2019;30 Suppl 4:iv65.
    PubMed    
    
    
    
87. NAZARIAN A, Sureshbabu S, Berman N, Wolf D, et al
    RENCA macrobead therapy (RMB): A biological-systems approach to metastatic colorectal cancer [U.S. FDA BB-IND 10091].
    Ann Oncol. 2019;30 Suppl 4:iv64.
    PubMed    
    
    
    
88. BURZ C, Bojan A, Balacescu L, Lisencu C, et al
    Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv63-iv64.
    PubMed    
    
    
    
89. SANCHEZ-CAMACHO A, Herrero Rivera D, Carrasco I, Limon M, et al
    Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution.
    Ann Oncol. 2019;30 Suppl 4:iv62.
    PubMed    
    
    
    
90. PREJAC J, Kekez D, Belev B, Plestina S, et al
    Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer: a single-centre retrospective cohort analysis of 186 patients.
    Ann Oncol. 2019;30 Suppl 4:iv62.
    PubMed    
    
    
    
91. TAMPAKIS A, Tampaki E, Nonni A, Patsouris E, et al
    L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease.
    Ann Oncol. 2019;30 Suppl 4:iv60.
    PubMed    
    
    
    
92. FORNER S, Summers J, Hill M, Mikropoulos C, et al
    Which patients on chemotherapy for colorectal cancer should be anticoagulated?
    Ann Oncol. 2019;30 Suppl 4:iv6.
    PubMed    
    
    
    
93. WONG S, Chiang C, Yeung S, Lee S, et al
    The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases.
    Ann Oncol. 2019;30 Suppl 4:iv58.
    PubMed    
    
    
    
94. BOUSAHBA A, Behourah Z
    Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab.
    Ann Oncol. 2019;30 Suppl 4:iv56.
    PubMed    
    
    
    
95. BAE J, Kye B, Lee Y, Lee I, et al
    Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv56.
    PubMed    
    
    
    
96. GRIDNEV D, Trandofilov M, Zhevelyuk A, Islamova D, et al
    The role of combined treatment of metastatic colorectal cancer in patients with liver metastases.
    Ann Oncol. 2019;30 Suppl 4:iv55.
    PubMed    
    
    
    
97. KR A, P SS, Kumar C R
    Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv54.
    PubMed    
    
    
    
98. KR A, P SS, Kumar C R
    Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Ann Oncol. 2019;30 Suppl 4:iv54.
    PubMed    
    
    
    
99. DUARTE S, Grilo I, Ladeira K, Pimenta J, et al
    Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences.
    Ann Oncol. 2019;30 Suppl 4:iv53.
    PubMed    
    
    
    
100. JAROSZ M, Rychlik E
     Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland.
     Ann Oncol. 2019;30 Suppl 4:iv53.
     PubMed    
     
     
     
101. APARICIO J, Virgili A, Capdevila J, Munoz Boza F, et al
     Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).
     Ann Oncol. 2019;30 Suppl 4:iv52.
     PubMed    
     
     
     
102. KR A, P SS, Kumar C R
     Complete peritonectomy versus selective peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes.
     Ann Oncol. 2019;30 Suppl 4:iv52.
     PubMed    
     
     
     
103. DE TORO CARMENA M, Ortega Moran L, Garcia Adrian S, Castanon Lopez C, et al
     Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients.
     Ann Oncol. 2019;30 Suppl 4:iv51-iv52.
     PubMed    
     
     
     
104. JAROSZ M, Rychlik E
     Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland.
     Ann Oncol. 2019;30 Suppl 4:iv50.
     PubMed    
     
     
     
105. PARK Y, Lee K, Lee J, Oh S, et al
     Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv5.
     PubMed    
     
     
     
106. FORMICA V, Nardecchia A, Morelli C, Lucchetti J, et al
     A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv48.
     PubMed    
     
     
     
107. MARTINEZ-LAGO N, Carmona Campos M, Gonzalez Villarroel P, Salgado Fernandez M, et al
     Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.
     Ann Oncol. 2019;30 Suppl 4:iv42-iv43.
     PubMed    
     
     
     
108. BOUDINAR F, Larbaoui B
     Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases.
     Ann Oncol. 2019;30 Suppl 4:iv41-iv42.
     PubMed    
     
     
     
109. ABDALLAH E, Souzae Silva V, Aguiar S Jr, Takahashi R, et al
     Circulating tumor cells levels correlate with carcinoembryonic antigen in patients with high-risk colon cancer who experienced disease progression.
     Ann Oncol. 2019;30 Suppl 4:iv41.
     PubMed    
     
     
     
110. CALDERILLO-RUIZ G, Lopez H, Herrera M, Trejo E, et al
     Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv40-iv41.
     PubMed    
     
     
     
111. CALDERILLO-RUIZ G, Lopez H, Padilla A, Diaz C, et al
     Surgery specialization as a prognostic factor in colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv40.
     PubMed    
     
     
     
112. CALDERILLO-RUIZ G, Lopez H, Diaz C, Ruiz-Garcia E, et al
     Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III.
     Ann Oncol. 2019;30 Suppl 4:iv39.
     PubMed    
     
     
     
113. RICCI V, Falletta A, Granetto C, Paccagnella M, et al
     Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib.
     Ann Oncol. 2019;30 Suppl 4:iv38.
     PubMed    
     
     
     
114. CALEGARI M, Zurlo I, Basso M, Orlandi A, et al
     Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study).
     Ann Oncol. 2019;30 Suppl 4:iv37-iv38.
     PubMed    
     
     
     
115. VERMORKEN J, Cervantes A, Morsing P, Johansson K, et al
     A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv36.
     PubMed    
     
     
     
116. SUN G, Gao P, Jia J, Zhang L, et al
     Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure.
     Ann Oncol. 2019;30 Suppl 4:iv36.
     PubMed    
     
     
     
117. FEDYANIN M, Chubenko V, Belonogov A, Beluhin S, et al
     Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study.
     Ann Oncol. 2019;30 Suppl 4:iv35.
     PubMed    
     
     
     
118. YU H, Yao X, Meng X
     A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism.
     Ann Oncol. 2019;30 Suppl 4:iv35-iv36.
     PubMed    
     
     
     
119. KIM C, Kim W, Han Y, Kim J, et al
     Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv35.
     PubMed    
     
     
     
120. GHIDINI M, Hahne J, Senti C, Lampis A, et al
     Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
     Ann Oncol. 2019;30 Suppl 4:iv34-iv35.
     PubMed    
     
     
     
121. ELBAIOMY M, Waheed A, Elkhodary T
     Prognostic value of lymph node ratio in lymph node-invaded colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv34.
     PubMed    
     
     
     
122. CUNHA R, Menezes M, Fernandes R, Oliveira A, et al
     Stage IIa colon cancer: adjuvant chemotherapy in real life.
     Ann Oncol. 2019;30 Suppl 4:iv32.
     PubMed    
     
     
     
123. GIULIANI J, Bonetti A
     The onset of grade>/=3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil.
     Ann Oncol. 2019;30 Suppl 4:iv31.
     PubMed    
     
     
     
124. LOMBARDI P, Marandino L, De Luca E, Zichi C, et al
     Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018.
     Ann Oncol. 2019;30 Suppl 4:iv29.
     PubMed    
     
     
     
125. TILBY M, Escola C, Ellison C, Narramneni L, et al
     Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience.
     Ann Oncol. 2019;30 Suppl 4:iv27.
     PubMed    
     
     
     
126. ISHIGURO A, Yuki S, Takahashi N, Shichinohe T, et al
     North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003).
     Ann Oncol. 2019;30 Suppl 4:iv24.
     PubMed    
     
     
     
127. FERNANDEZ MONTES A, Martinez Lago N, De la Camara Gomez J, Covela Rua M, et al
     FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.
     Ann Oncol. 2019;30 Suppl 4:iv23-iv24.
     PubMed    
     
     
     
128. SFAKIANAKI M, Papadaki C, Tzardi M, Trypaki M, et al
     PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv21-iv22.
     PubMed    
     
     
     
129. ZAREV I, Maksimovic M, Ljubisavljevic R, Bozovic M, et al
     Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv21.
     PubMed    
     
     
     
130. CHEONG C, Suh K
     Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features.
     Ann Oncol. 2019;30 Suppl 4:iv20.
     PubMed    
     
     
     
131. ROSATI G, Cordio S, Reggiardo G, Aprile G, et al
     Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies.
     Ann Oncol. 2019;30 Suppl 4:iv19-iv20.
     PubMed    
     
     
     
132. NOGUEIRA-COSTA G, Fernandes I, Guerra-Pereira N, Gameiro R, et al
     Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role.
     Ann Oncol. 2019;30 Suppl 4:iv18.
     PubMed    
     
     
     
133. FEDYANIN M, Chekini D, Chubenko V, Tjulandin S, et al
     Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis.
     Ann Oncol. 2019;30 Suppl 4:iv16.
     PubMed    
     
     
     
134. PAPAMICHAEL D, Kountourakis P, Papanastasopoulos P, Xenophontos E, et al
     Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years.
     Ann Oncol. 2019;30 Suppl 4:iv16.
     PubMed    
     
     
     
135. KOGAN Y, Elishmereni M, Taub E, Agur Z, et al
     (late submission poster) The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv155.
     PubMed    
     
     
     
136. KOPETZ S, Grothey A, Van Cutsem E, Yaeger R, et al
     BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv154.
     PubMed    
     
     
     
137. CASADEI GARDINI A, Gelsomino F, Spallanzani A, Tamburini E, et al
     Is there an optimal choice in refractory colorectal cancer? A network meta-analysis.
     Ann Oncol. 2019;30 Suppl 4:iv14.
     PubMed    
     
     
     
138. ANGELIS V, Young T, Vasiliadou I, Hill M, et al
     Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv14.
     PubMed    
     
     
     
139. CASE A, Arif S
     The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation.
     Ann Oncol. 2019;30 Suppl 4:iv14.
     PubMed    
     
     
     
140. ARGILES G, Margalef NM, Valladares-Ayerbes M, de Prado JV, et al
     Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).
     Ann Oncol. 2019;30 Suppl 4:iv135.
     PubMed    
     
     
     
141. PIETRANTONIO F, Lobefaro R, Antista M, Miceli R, et al
     A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv135.
     PubMed    
     
     
     
142. GALON J, Hermitte F, Mlecnik B, Marliot F, et al
     Significant differences in outcome between Immunoscore categories in stage I colon cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv134.
     PubMed    
     
     
     
143. GAMBARO K, Marques M, McNamara S, du Tertre MC, et al
     Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy.
     Ann Oncol. 2019;30 Suppl 4:iv133.
     PubMed    
     
     
     
144. ELIZABETH A, Jansen L, Hendrik B, Kloor M, et al
     Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
     Ann Oncol. 2019;30 Suppl 4:iv132.
     PubMed    
     
     
     
145. MYER P, Lee J, Madison R, Newberg J, et al
     Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry.
     Ann Oncol. 2019;30 Suppl 4:iv132.
     PubMed    
     
     
     
146. WATANABE J, Sato T, Kagawa Y, Oki E, et al
     SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv132.
     PubMed    
     
     
     
147. PFEIFFER P, Glimelius B, Winther S, Qvortrup C, et al
     Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results.
     Ann Oncol. 2019;30 Suppl 4:iv131.
     PubMed    
     
     
     
148. PARIKH A, Van Seventer E, Boland G, Hartwig A, et al
     Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv131.
     PubMed    
     
     
     
149. PFEIFFER P, Yilmaz M, Moller S, Zitnjak D, et al
     Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial.
     Ann Oncol. 2019;30 Suppl 4:iv130-iv131.
     PubMed    
     
     
     
150. GARRALDA E, Fiedler W, Matos I, Rolling C, et al
     Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.
     Ann Oncol. 2019;30 Suppl 4:iv125.
     PubMed    
     
     
     
151. SALEH M, Cassier P, Eberst L, Naik G, et al
     Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study.
     Ann Oncol. 2019;30 Suppl 4:iv124.
     PubMed    
     
     
     
152. VAN CUTSEM E, Machiels J, Van den Eynde M, Prenen H, et al
     Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv124-iv125.
     PubMed    
     
     
     
153. GEISSLER M, Tannapfel A, Reinacher-Schick A, Martens U, et al
     Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).
     Ann Oncol. 2019;30 Suppl 4:iv119-iv120.
     PubMed    
     
     
     
154. DUCREUX M, O'Connor J, Dochy E, Fiala-Buskies S, et al
     Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv119.
     PubMed    
     
     
     
155. OSTERLUND P, Lamminmaki A, Soveri L, Algars A, et al
     Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study.
     Ann Oncol. 2019;30 Suppl 4:iv119.
     PubMed    
     
     
     
156. HOFHEINZ R, Scholten F, Derigs H, Thaler J, et al
     Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113).
     Ann Oncol. 2019;30 Suppl 4:iv118.
     PubMed    
     
     
     
157. ROSSINI D, Pagani F, Pellino A, Dell'Aquila E, et al
     Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis.
     Ann Oncol. 2019;30 Suppl 4:iv118.
     PubMed    
     
     
     
158. MAURI G, Kanter K, Fish M, Horick N, et al
     PARP-ness in metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv117.
     PubMed    
     
     
     
159. DAS R, Ou F, Washburn C, Innocenti F, et al
     Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).
     Ann Oncol. 2019;30 Suppl 4:iv116.
     PubMed    
     
     
     
160. SALVATORE L, Bria E, Sperduti I, Hinke A, et al
     Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies.
     Ann Oncol. 2019;30 Suppl 4:iv116.
     PubMed    
     
     
     
161. CARDONE C, Blauensteiner B, Moreno-Viedma V, Paul M, et al
     Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS.
     Ann Oncol. 2019;30 Suppl 4:iv116.
     PubMed    
     
     
     
162. RAIMONDI A, Di Maio M, Peverelli G, Morano F, et al
     Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study.
     Ann Oncol. 2019;30 Suppl 4:iv115.
     PubMed    
     
     
     
163. LAM K, Ko J, Chan A, Choi H, et al
     Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv115-iv116.
     PubMed    
     
     
     
164. SUNAKAWA Y, Nakamura M, Ishizaki M, Kataoka M, et al
     RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
     Ann Oncol. 2019;30 Suppl 4:iv114.
     PubMed    
     
     
     
165. ROSSINI D, Sbrana A, Bergamo F, Manai C, et al
     Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies.
     Ann Oncol. 2019;30 Suppl 4:iv114-iv115.
     PubMed    
     
     
     
166. OSTERMAN E, Mezheyeuski A, Sjoblom T, Glimelius B, et al
     Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort.
     Ann Oncol. 2019;30 Suppl 4:iv113.
     PubMed    
     
     
     
167. VIEITEZ DE PRADO J, Encinas Garcia S, Grande Pulido E, Sanchez Nieto R, et al
     Cost of metastatic colorectal cancer drugs per month of life gained in Spain.
     Ann Oncol. 2019;30 Suppl 4:iv11.
     PubMed    
     
     
     
168. RADWI A, Asiri I, Asiri M, Khudhayri A, et al
     Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv11-iv12.
     PubMed    
     
     
     
169. GROTHEY A, Yaeger R, Paez D, Tabernero J, et al
     ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).
     Ann Oncol. 2019;30 Suppl 4:iv109.
     PubMed    
     
     
     
170. SGHAIER S, Rachdi H, Mejri N, Graja B, et al
     How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases.
     Ann Oncol. 2019;30 Suppl 4:iv108-iv109.
     PubMed    
     
     
     
171. SATAPATHY S, Sjolander A
     15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-alpha dependent phenomenon.
     Ann Oncol. 2019;30 Suppl 4:iv107.
     PubMed    
     
     
     
172. CARNERERO CORDOBA L, Gonzalez Cebrian I, Rodriguez Gonzalez C, Gonzalez-Flores E, et al
     Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population.
     Ann Oncol. 2019;30 Suppl 4:iv106.
     PubMed    
     
     
     
173. KIM S, Kim S
     Interleukin-6 induced Lipocalin 2 promotes tumorigenesis from colitis to colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv105-iv106.
     PubMed    
     
     
     
174. BERRAD S, Oualla K, Nouiyakh L, Erraichi H, et al
     Survival and prognostic factors for stage II colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv105.
     PubMed    
     
     
     
175. BEKOUACI S, Smaili F
     Are hepatic metastases of colorectal cancer more chemosensitive than other metastatic sites?
     Ann Oncol. 2019;30 Suppl 4:iv104.
     PubMed    
     
     
     
176. SHIN R, Park J, Jeong S, Heo S, et al
     Clinicopathologic feature of microsatellite stable early-onset colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv104.
     PubMed    
     
     
     
177. BEKOUACI S, Smaili F
     Clinico-epidemiological profile of colorectal cancer in Algerian patients age 40 and under: Alarming increase in incidence.
     Ann Oncol. 2019;30 Suppl 4:iv103-iv104.
     PubMed    
     
     
     
178. SIMOES J, Fernandes C, Borges C, Melo R, et al
     Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv101.
     PubMed    
     
     
     
179. STREICH G, Batagelj E, Dimase F, Martinez D, et al
     Home chemotherapy in colorectal cancer: First experience in Argentina.
     Ann Oncol. 2019;30 Suppl 4:iv101.
     PubMed    
     
     
     
180. ELKHOULY E, Gohar S, Abelela D, Fakhry T, et al
     Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv100-iv101.
     PubMed    
     
     
     
181. TOPI G, Satapathy S, Dash P, Ehrnstrom R, et al
     High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv100.
     PubMed    
     
     
     
182. RAMIREZ DAFFOS P, Gonzalez-Astorga B, Jimenez E, Rubiales S, et al
     Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities.
     Ann Oncol. 2019;30 Suppl 4:iv10-iv11.
     PubMed    
     
     
     
183. MURO K, Uetake H, Tsuchihara K, Shitara K, et al
     PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv10.
     PubMed    
     
     
     
184. ZOK J, Radecka B, Adamowicz K, Korniluk J, et al
     Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv10.
     PubMed    
     
     
     
185. KRUCHININA M, Gromov A, Prudnikova I, Shashkov M, et al
     Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics.
     Ann Oncol. 2019;30 Suppl 4:iv1.
     PubMed    
     
     
     June 2019
186. SOUGLAKOS J, Boukovinas I, Kakolyris S, Xynogalos S, et al
     Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherap
     Ann Oncol. 2019 Jun 22. pii: 5522015. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2019
187. HAMFJORD J, Guren TK, Dajani O, Johansen JS, et al
     Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.
     Ann Oncol. 2019 May 2. pii: 5482571. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. SANTOS C, Azuara D, Vieitez JM, Paez D, et al
     Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
     Ann Oncol. 2019;30:796-803.
     PubMed     Abstract available
     
     
     April 2019
189. SCHROCK AB, Ouyang C, Sandhu J, Sokol E, et al
     Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
     Ann Oncol. 2019 Apr 30. pii: 5482063. doi: 10.1093.
     PubMed     Abstract available
     
     
     
190. FONTANA E, Eason K, Cervantes A, Salazar R, et al
     Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.
     Ann Oncol. 2019;30:520-527.
     PubMed     Abstract available
     
     
     
191. GUNTER MJ, Alhomoud S, Arnold M, Brenner H, et al
     Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
     Ann Oncol. 2019;30:510-519.
     PubMed     Abstract available
     
     
     March 2019
192. SANTOS C, Azuara D, Vieitez JM, Paez D, et al
     Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
     Ann Oncol. 2019 Mar 6. pii: 5370172. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2019
193. FONTANA E, Eason K, Cervantes A, Salazar R, et al
     Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials.
     Ann Oncol. 2019 Feb 23. pii: 5364014. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. GUNTER MJ, Alhomoud S, Arnold M, Brenner H, et al
     Meeting Report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
     Ann Oncol. 2019 Feb 5. pii: 5307027. doi: 10.1093.
     PubMed     Abstract available
     
     
     
195. SINGH AV
     21PEvaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
     Ann Oncol. 2019;30.
     PubMed    
     
     
     
196. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
     20PNischarin expression in colon cancer.
     Ann Oncol. 2019;30.
     PubMed    
     
     
     
197. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
     19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
     Ann Oncol. 2019;30.
     PubMed    
     
     
     
198. SHITARA K, Yamanaka T, Denda T, Tsuji Y, et al
     REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
     Ann Oncol. 2019;30:259-265.
     PubMed     Abstract available
     
     
     
199. SIRAVEGNA G, Bardelli A
     Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
     Ann Oncol. 2019;30:157-159.
     PubMed    
     
     
     
200. SINGH AV
     Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
     Ann Oncol. 2019;30 Suppl 1:i8.
     PubMed    
     
     
     
201. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
     Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
     Ann Oncol. 2019;30 Suppl 1:i7.
     PubMed    
     
     
     
202. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
     Nischarin expression in colon cancer.
     Ann Oncol. 2019;30 Suppl 1:i7-i8.
     PubMed    
     
     
     January 2019
203. VIDAL J, Bellosillo B, Santos Vivas C, Garcia-Alfonso P, et al
     Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
     Ann Oncol. 2019 Jan 23. pii: 5299439. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2018
204. SHITARA K, Yamanaka T, Denda T, Tsuji Y, et al
     REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients.
     Ann Oncol. 2018 Dec 3. pii: 5227619. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2018
205. SIRAVEGNA G, Bardelli A
     Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
     Ann Oncol. 2018 Nov 26. pii: 5209692. doi: 10.1093.
     PubMed    
     
     
     October 2018
206. WANG Y, Jones JC, Kipp BR, Grothey A, et al
     Activity of EGFR Antibody in Non-V600 BRAF Mutant Metastatic Colorectal Cancer.
     Ann Oncol. 2018 Oct 26. pii: 5145082. doi: 10.1093.
     PubMed    
     
     
     September 2018
207. MOOI JK, Wirapati P, Asher R, Lee CK, et al
     The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
     Ann Oncol. 2018 Sep 21. pii: 5104878. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2018
208. MAURI G, Bencardino K, Sartore-Bianchi A, Siena S, et al
     Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.
     Ann Oncol. 2018 Jul 28. pii: 5061139. doi: 10.1093.
     PubMed    
     
     
     
209. VAN CUTSEM E, Yoshino T, Lenz HJ, Lonardi S, et al
     Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
     Ann Oncol. 2018 Jul 13. pii: 5053583. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. OVERMAN MJ, Adam L, Raghav K, Wang J, et al
     Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
     Ann Oncol. 2018 Jul 3. pii: 5048416. doi: 10.1093.
     PubMed    
     
     
     June 2018
211. SARTORE-BIANCHI A, Siena S
     The right chance for temozolomide in metastatic colorectal cancer?
     Ann Oncol. 2018 Jun 25. pii: 5044274. doi: 10.1093.
     PubMed    
     
     
     
212. SOBRERO A, Douillard JY
     Reply to the Letter to the Editor: "The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?" By P. Trendsz et al.
     Ann Oncol. 2018 Jun 15. pii: 5038506. doi: 10.1093.
     PubMed    
     
     
     
213. TAN RYC, Camat MD, Ng M, Lim TH, et al
     HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients.
     Ann Oncol. 2018 Jun 3. pii: 5001837. doi: 10.1093.
     PubMed    
     
     
     May 2018
214. MORANO F, Corallo S, Niger M, Barault L, et al
     Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
     Ann Oncol. 2018 May 31. pii: 5026003. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. TRENSZ P, Calvel L, Kurtz JE
     The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
     Ann Oncol. 2018 May 22. pii: 5001429. doi: 10.1093.
     PubMed    
     
     
     April 2018
216. APARICIO T, Bouche O, Taieb J, Maillard E, et al
     Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
     Ann Oncol. 2018 Apr 30. pii: 4990353. doi: 10.1093.
     PubMed    
     
     
     
217. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
     Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
     Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
     Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.
     Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
     PubMed     Abstract available
     
     
     
219. SANTOS C, Sanz-Pamplona R, Salazar R
     RET-fusions: a novel paradigm in colorectal cancer.
     Ann Oncol. 2018 Apr 10. pii: 4965879. doi: 10.1093.
     PubMed    
     
     
     
220. SIENA S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, et al
     Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
     Ann Oncol. 2018 Apr 6. pii: 4962457. doi: 10.1093.
     PubMed     Abstract available
     
     
     
221. MASUISHI T, Taniguchi H, Sugiyama K, Kato K, et al
     Eribulin in BRAF V600E mutant metastatic colorectal cancer: Case series and potential rationale.
     Ann Oncol. 2018 Apr 4. pii: 4959907. doi: 10.1093.
     PubMed    
     
     
     March 2018
222. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
     European cancer mortality predictions for the year 2018 with focus on colorectal cancer.
     Ann Oncol. 2018 Mar 19. pii: 4935197. doi: 10.1093.
     PubMed     Abstract available
     
     
     
223. MONTAGUT C, Tsui DW, Diaz LA Jr.
     Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?
     Ann Oncol. 2018 Mar 14. pii: 4937227. doi: 10.1093.
     PubMed    
     
     
     
224. SMEBY J, Sveen A, Merok MA, Danielsen SA, et al
     CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
     Ann Oncol. 2018 Mar 5. pii: 4922418. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. VIVANCOS A, Elez E, Salazar R
     Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
     Ann Oncol. 2018;29:532-534.
     PubMed    
     
     
     
226. SCHOU JV, Larsen FO, Sorensen BS, Abrantes R, et al
     Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
     Ann Oncol. 2018;29:610-615.
     PubMed     Abstract available
     
     
     February 2018
227. ARNOLD D, Prager GW, Quintela A, Stein A, et al
     Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
     Ann Oncol. 2018 Feb 14. pii: 4857261. doi: 10.1093.
     PubMed     Abstract available
     
     
     
228. BACHET JB, Bouche O, Taieb J, Dubreuil O, et al
     RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
     Ann Oncol. 2018 Feb 9. pii: 4846852. doi: 10.1093.
     PubMed     Abstract available
     
     
     
229. CARR PR, Alwers E, Bienert S, Weberpals J, et al
     Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses.
     Ann Oncol. 2018 Feb 9. pii: 4846850. doi: 10.1093.
     PubMed     Abstract available
     
     
     
230. SOBRERO A, Grothey A, Iveson T, Labianca R, et al
     The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?
     Ann Oncol. 2018 Feb 9. pii: 4846853. doi: 10.1093.
     PubMed     Abstract available
     
     
     
231. WILLIS JA, Vilar E
     Pharmacogenomics: time to rethink its role in precision medicine.
     Ann Oncol. 2018;29:293-295.
     PubMed    
     
     
     January 2018
232. SOBHANI I, Itti E, Luciani A, Baumgaertner I, et al
     Colorectal Cancer (CRC) Monitoring by Six-Monthly 18FDG-PET/CT: An Open-Label Multicentre Randomised Trial.
     Ann Oncol. 2018 Jan 22. pii: 4819113. doi: 10.1093.
     PubMed     Abstract available
     
     
     
233. CARMELIET P, Li X, Treps L, Conradi LC, et al
     RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients.
     Ann Oncol. 2018 Jan 19. pii: 4817343. doi: 10.1093.
     PubMed    
     
     
     
234. PARK JH, McMillan DC
     Outcome in colorectal cancer - tumour, stroma and so much more.
     Ann Oncol. 2018 Jan 8. pii: 4792956. doi: 10.1093.
     PubMed    
     
     
     
235. DELL'AQUILA E, Cremolini C, Zeppola T, Lonardi S, et al
     Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
     Ann Oncol. 2018 Jan 8. pii: 4793700. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2017
236. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
     Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
     Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
     PubMed     Abstract available
     
     
     
237. DANIELSEN HE, Hveem TS, Domingo E, Pradhan M, et al
     Prognostic markers for colorectal cancer; estimating ploidy and stroma.
     Ann Oncol. 2017 Dec 27. pii: 4779924. doi: 10.1093.
     PubMed     Abstract available
     
     
     
238. YAMADA Y, Denda T, Gamoh M, Iwanaga I, et al
     S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial.
     Ann Oncol. 2017 Dec 27. pii: 4779925. doi: 10.1093.
     PubMed     Abstract available
     
     
     
239. GONG J, Tian J, Lou J, Wang X, et al
     A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267.
     Ann Oncol. 2017 Dec 18. pii: 4756051. doi: 10.1093.
     PubMed     Abstract available
     
     
     
240. ORDONEZ-ME JM, Walter V, Schottker B, Jenab M, et al
     Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
     Ann Oncol. 2017 Dec 13. pii: 4735153. doi: 10.1093.
     PubMed     Abstract available
     
     
     
241. TABERNERO J, Hozak RR, Yoshino T, Cohn AL, et al
     Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study.
     Ann Oncol. 2017 Dec 7. pii: 4708229. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2017
242. YOSHINO T, Arnold D, Taniguchi H, Pentheroudakis G, et al
     Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
     Ann Oncol. 2017 Nov 16. doi: 10.1093.
     PubMed     Abstract available
     
     
     
243. ABAD A, Martinez-Balibrea E, Vieitez JM, Orduna VA, et al
     Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
     Ann Oncol. 2017 Nov 14. doi: 10.1093.
     PubMed     Abstract available
     
     
     
244. DIENSTMANN R, Guinney J
     Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.
     Ann Oncol. 2017;28:2889-2890.
     PubMed    
     
     
     October 2017
245. OVERMAN M, Adam L, Raghav K, Wang J, et al
     Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
     Ann Oncol. 2017 Oct 23. doi: 10.1093.
     PubMed     Abstract available
     
     
     
246. TARAZONA N, Cervantes A
     Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
     Ann Oncol. 2017 Oct 10. doi: 10.1093.
     PubMed    
     
     
     
247. SCIALLERO S, Battistuzzi L, Varesco L
     Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
     Ann Oncol. 2017;28:2620-2621.
     PubMed    
     
     
     
248. CASADEI GARDINI A, Valgiusti M, Passardi A, Frassineti GL, et al
     Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?
     Ann Oncol. 2017;28:2620.
     PubMed    
     
     
     September 2017
249. APARICIO T, Bouche O, Taieb J, Maillard E, et al
     Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
     Ann Oncol. 2017 Sep 28. doi: 10.1093.
     PubMed     Abstract available
     
     
     
250. CREMOLINI C, Morano F, Moretto R, Berenato R, et al
     Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
     Ann Oncol. 2017 Sep 25. doi: 10.1093.
     PubMed     Abstract available
     
     
     
251. GARCIA-FONCILLAS J, Alba E, Aranda E, Diaz-Rubio E, et al
     Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
     Ann Oncol. 2017 Sep 4. doi: 10.1093.
     PubMed     Abstract available
     
     
     
252. SIENA S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, et al
     Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.
     Ann Oncol. 2017 Sep 4. doi: 10.1093.
     PubMed     Abstract available
     
     
     
253. SOBRERO A, Damiani A
     Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
     Ann Oncol. 2017;28:2043-2044.
     PubMed    
     
     
     
254. WEI Q, Ye Z, Zhong X, Li L, et al
     Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
     Ann Oncol. 2017;28:2135-2141.
     PubMed     Abstract available
     
     
     
255. GOEY KKH, Elias SG, van Tinteren H, Lacle MM, et al
     Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
     Ann Oncol. 2017;28:2128-2134.
     PubMed     Abstract available
     
     
     August 2017
256. NORMANNO N, Esposito Abate R, Lambiase M, Forgione L, et al
     RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
     Ann Oncol. 2017 Aug 7. doi: 10.1093.
     PubMed     Abstract available
     
     
     
257. BERGER MD, Stintzing S, Heinemann V, Yang D, et al
     Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
     Ann Oncol. 2017 Aug 2. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2017
258. SANZ-GARCIA E, Argiles G, Elez E, Tabernero J, et al
     BRAF mutant Colorectal Cancer: prognosis, treatment and new perspectives.
     Ann Oncol. 2017 Jul 24. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2017
259. SCHLESINGER S, Aleksandrova K, Abar L, Vieria AR, et al
     Adult weight gain and colorectal adenomas-a systematic review and meta-analysis.
     Ann Oncol. 2017;28:1217-1229.
     PubMed     Abstract available
     
     
     May 2017
260. OTT PA, Piha-Paul SA, Munster P, Pishvaian MJ, et al
     Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
     Ann Oncol. 2017;28:1036-1041.
     PubMed     Abstract available
     
     
     March 2017
261. ROMBOUTS AJM, Hugen N, Elferink MAG, Feuth T, et al
     Incidence of second tumors after treatment with or without radiation for rectal cancer.
     Ann Oncol. 2017;28:535-540.
     PubMed     Abstract available
     
     
     February 2017
262. PATEL UB, Brown G, Machado I, Santos-Cores J, et al
     MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
     Ann Oncol. 2017;28:344-353.
     PubMed     Abstract available
     
     
     
263. YANG TO, Cairns BJ, Reeves GK, Green J, et al
     Cancer risk among 21st century blood transfusion recipients.
     Ann Oncol. 2017;28:393-399.
     PubMed     Abstract available
     
     
     
264. GLYNNE-JONES R
     Adding extra dimensions in rectal cancer theory.
     Ann Oncol. 2017;28:198-200.
     PubMed    
     
     
     January 2017
265. POWELL MA
     Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
     Ann Oncol. 2017;28:9-10.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: